Compare Mongodb Inc (MDB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Organon & Co. Common Stock — how do they compare? Mongodb Inc trades at $348.69 (market cap $30.05B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Mongodb Inc is far larger — about 8.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Organon & Co. Common Stock for 0 Days on average.
| MDB | OGN | |
|---|---|---|
Market Cap | $30.05B | $3.62B |
Volume | 3,027,814 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $472.29 | $13.81 |
52-Week Low | $225.95 | $5.70 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $27.67B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $356.29, down 6.56% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Revenue has grown from $874 million in 2022 to $2.01 billion in 2025, though net losses persist, narrowing to -$129 million in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
The outlook is cautiously optimistic, with a consensus price target of $456.76 implying 28% upside. Key opportunities include raised long-term revenue targets exceeding 20% growth and AI-driven product expansion. Risks involve continued net losses, high valuation multiples, and execution challenges amid leadership changes. Analyst consensus is strongly bullish with 80% buy ratings, but stock volatility may persist near-term.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
